glp 1 prescription canada approves first generic GLP-1 drug in G7 WHO backs GLP-1 meds to

rskov, Holst, Seier, Poulsen, Kirkegaard)

Results announced in December 2025 confirmed the Phase 2 findings at a longer timepoint (Lilly Press Release, Dec 2025): The 28.7% weight loss at 68 weeks exceeds both semaglutide (~15% in STEP trials) and tirzepatide (~22.5% in SURMOUNT trials) at similar timepoints

The Institute for Clinical and Economic Review (ICER) found that the lifetime employer cost for Wegovy would be $274,400 , while the medical costs averted over a lifetime would be $61,600

One of the studies, SUSTAIN-6, was a 2-year FDA-mandated cardiovascular-outcomes trial involving 3297 patients

Retatrutide is investigational